Cover
| Cover | 12 Months Ended |
| Dec. 31, 2022 | |
| Document Information [Line Items] | |
| Document Type | DEF 14A |
| Amendment Flag | false |
| Entity Information [Line Items] | |
| Entity Registrant Name | Thermo Fisher Scientific Inc. |
| Entity Central Index Key | 0000097745 |
Pay vs Performance Disclosure
| Pay vs Performance Disclosure | 12 Months Ended | 36 Months Ended | |||
| Dec. 31, 2022 USD ($) $ / shares | Dec. 31, 2021 USD ($) $ / shares | Dec. 31, 2020 USD ($) $ / shares | Dec. 31, 2022 | ||
| Pay vs Performance Disclosure [Table] | |||||
| Pay vs Performance [Table Text Block] | Pay versus performance As required by SEC rules, we are providing the following information about the relationship between executive compensation actually paid (as defined by SEC rules) and certain financial performance measures. For information about how our Compensation Committee seeks to align executive compensation with the Company’s performance, see “Compensation discussion and analysis.” The amounts in the table below are calculated in accordance with SEC rules and do not represent amounts actually earned or realized by our NEOs. Pay versus performance table Year Summary Compensation Actually Paid to CEO (1) Average Summary Compensation Table Total for Non-CEO Named Executive Officers (2) Average Compensation Actually Paid to Non-CEO Named Executive Officers (1) Value of Initial Fixed $100 Net Company Selected Measure (Adjusted EPS) (5) Total Shareholder Return (3) Peer Group Total Shareholder Return (4) 2022 $ 28,208,909 $ (4,695,030) $ 5,944,038 $ (639,700) $ 170.63 $ 137.66 $ 6.960 $ 23.24 2021 $ 21,234,358 $ 65,926,795 $ 8,235,368 $ 23,903,448 $ 206.28 $ 141.38 $ 7.728 $ 25.13 2020 $ 26,390,073 $ 79,705,130 $ 8,981,197 $ 27,907,550 $ 143.71 $ 112.97 $ 6.377 $ 19.56 (1) Represents the amount of “Compensation Actually Paid” or “CAP” as computed per SEC rules. These amounts do not reflect the actual amount of compensation earned by or paid to the applicable individual(s) during the applicable year. The following table summarizes the adjustments made to total compensation in accordance with Item 402(v) of Regulation S-K in order to determine the compensation amounts shown in the table above as being “Compensation Actually Paid”. Adjustments 2022 2021 2020 CEO Other NEOs* CEO Other NEOs* CEO Other NEOs* Total Compensation from Summary Compensation Table (“SCT”) $ 28,208,909 $ 5,944,038 $ 21,234,358 $ 8,235,368 $ 26,390,073 $ 8,981,197 Adjustments for defined benefit and actuarial pension plans (Subtraction): SCT amounts $ — $ — $ — $ — $ — $ (158,701) Adjustments for stock and option awards** (Subtraction): SCT amounts $ (20,198,218) $ (3,416,337) $ (12,551,562) $ (5,251,850) $ (16,282,896) $ (5,319,794) Addition: Fair value at year end of awards granted during the covered fiscal year that are outstanding and unvested at year end $ 13,253,670 $ 3,626,807 $ 26,760,316 $ 10,357,430 $ 31,993,253 $ 10,441,378 Addition (Subtraction): Year-over-year change in fair value of awards granted in any prior fiscal year that are outstanding and unvested at year end $ (15,113,021) $ (4,391,710) $ 32,315,930 $ 10,136,736 $ 37,866,345 $ 11,887,160 Addition: Vesting date fair value of awards granted and vesting during such year $ 399,670 $ 109,219 $ 762,602 $ 269,259 $ 823,466 $ 270,477 Addition (Subtraction): Change as of the vesting date (from the end of the prior fiscal year) in fair value of awards granted in any prior fiscal year for which vesting conditions were satisfied during such year $ (11,246,041) $ (2,511,717) $ (2,594,849) $ 156,505 $ (1,085,111) $ 1,805,834 Compensation Actually Paid (as calculated) $ (4,695,030) $ (639,700) $ 65,926,795 $ 23,903,448 $ 79,705,130 $ 27,907,550 * Amounts presented are averages for the entire group of NEOs (excluding our CEO). ** Stock option grant date fair values are calculated based on the Black-Scholes option pricing model as of date of grant. Adjustments have been made using stock option fair values as of each measurement date using the stock price as of the measurement date and updated assumptions (i.e., term, volatility, dividend yield, risk free rates) as of the measurement date. Performance-based restricted stock unit grant date fair values are calculated using the stock price and performance accrual modifiers, where relevant, as of date of grant assuming target performance. Adjustments have been made using the stock price and performance accrual modifier as of the applicable year end and as of the date of vest. Time-vested restricted stock unit grant date fair values are calculated using the stock price as of date of grant. Adjustments have been made using the stock price as of the applicable year end and as of each date of vest. (2) The CEO was Mr. Casper for all years in the table. The other NEOs were Messrs Williamson and Lagarde (all years), Mr. Pettiti (2022 and 2021), Mr. Boxer (2022), Mr. Stevenson (2021 and 2020), and Syed Jafry (2020). (3) For the relevant fiscal year, represents the cumulative total shareholder return of the Company for the measurement periods ending on December 31 of each of 2022, 2021 and 2020, respectively. (4) For the relevant fiscal year, represents the cumulative total shareholder return of a weighted blend (80/20, respectively) of the Standard & Poor’s 500 Healthcare and Standard & Poor’s 500 Industrial Indices (“S&P Index”), our published industry index for purposes of disclosure under Item 201(e) of Regulation S-K, for the measurement periods ending on December 31 of each of 2022, 2021 and 2020, respectively. | ||||
| Company Selected Measure Name | [1] | Adjusted EPS | |||
| Named Executive Officers, Footnote [Text Block] | The CEO was Mr. Casper for all years in the table. The other NEOs were Messrs Williamson and Lagarde (all years), Mr. Pettiti (2022 and 2021), Mr. Boxer (2022), Mr. Stevenson (2021 and 2020), and Syed Jafry (2020). | ||||
| Peer Group Issuers, Footnote [Text Block] | For the relevant fiscal year, represents the cumulative total shareholder return of a weighted blend (80/20, respectively) of the Standard & Poor’s 500 Healthcare and Standard & Poor’s 500 Industrial Indices (“S&P Index”), our published industry index for purposes of disclosure under Item 201(e) of Regulation S-K, for the measurement periods ending on December 31 of each of 2022, 2021 and 2020, respectively. | ||||
| PEO Total Compensation Amount | $ 28,208,909 | $ 21,234,358 | $ 26,390,073 | ||
| PEO Actually Paid Compensation Amount | [2] | (4,695,030) | 65,926,795 | 79,705,130 | |
| Adjustment To PEO Compensation, Footnote [Text Block] | Adjustments 2022 2021 2020 CEO Other NEOs* CEO Other NEOs* CEO Other NEOs* Total Compensation from Summary Compensation Table (“SCT”) $ 28,208,909 $ 5,944,038 $ 21,234,358 $ 8,235,368 $ 26,390,073 $ 8,981,197 Adjustments for defined benefit and actuarial pension plans (Subtraction): SCT amounts $ — $ — $ — $ — $ — $ (158,701) Adjustments for stock and option awards** (Subtraction): SCT amounts $ (20,198,218) $ (3,416,337) $ (12,551,562) $ (5,251,850) $ (16,282,896) $ (5,319,794) Addition: Fair value at year end of awards granted during the covered fiscal year that are outstanding and unvested at year end $ 13,253,670 $ 3,626,807 $ 26,760,316 $ 10,357,430 $ 31,993,253 $ 10,441,378 Addition (Subtraction): Year-over-year change in fair value of awards granted in any prior fiscal year that are outstanding and unvested at year end $ (15,113,021) $ (4,391,710) $ 32,315,930 $ 10,136,736 $ 37,866,345 $ 11,887,160 Addition: Vesting date fair value of awards granted and vesting during such year $ 399,670 $ 109,219 $ 762,602 $ 269,259 $ 823,466 $ 270,477 Addition (Subtraction): Change as of the vesting date (from the end of the prior fiscal year) in fair value of awards granted in any prior fiscal year for which vesting conditions were satisfied during such year $ (11,246,041) $ (2,511,717) $ (2,594,849) $ 156,505 $ (1,085,111) $ 1,805,834 Compensation Actually Paid (as calculated) $ (4,695,030) $ (639,700) $ 65,926,795 $ 23,903,448 $ 79,705,130 $ 27,907,550 * Amounts presented are averages for the entire group of NEOs (excluding our CEO). ** Stock option grant date fair values are calculated based on the Black-Scholes option pricing model as of date of grant. Adjustments have been made using stock option fair values as of each measurement date using the stock price as of the measurement date and updated assumptions (i.e., term, volatility, dividend yield, risk free rates) as of the measurement date. Performance-based restricted stock unit grant date fair values are calculated using the stock price and performance accrual modifiers, where relevant, as of date of grant assuming target performance. Adjustments have been made using the stock price and performance accrual modifier as of the applicable year end and as of the date of vest. Time-vested restricted stock unit grant date fair values are calculated using the stock price as of date of grant. Adjustments have been made using the stock price as of the applicable year end and as of each date of vest. | ||||
| Non-PEO NEO Average Total Compensation Amount | [3] | 5,944,038 | 8,235,368 | 8,981,197 | |
| Non-PEO NEO Average Compensation Actually Paid Amount | [2] | (639,700) | 23,903,448 | 27,907,550 | |
| Adjustment to Non-PEO NEO Compensation Footnote [Text Block] | Adjustments 2022 2021 2020 CEO Other NEOs* CEO Other NEOs* CEO Other NEOs* Total Compensation from Summary Compensation Table (“SCT”) $ 28,208,909 $ 5,944,038 $ 21,234,358 $ 8,235,368 $ 26,390,073 $ 8,981,197 Adjustments for defined benefit and actuarial pension plans (Subtraction): SCT amounts $ — $ — $ — $ — $ — $ (158,701) Adjustments for stock and option awards** (Subtraction): SCT amounts $ (20,198,218) $ (3,416,337) $ (12,551,562) $ (5,251,850) $ (16,282,896) $ (5,319,794) Addition: Fair value at year end of awards granted during the covered fiscal year that are outstanding and unvested at year end $ 13,253,670 $ 3,626,807 $ 26,760,316 $ 10,357,430 $ 31,993,253 $ 10,441,378 Addition (Subtraction): Year-over-year change in fair value of awards granted in any prior fiscal year that are outstanding and unvested at year end $ (15,113,021) $ (4,391,710) $ 32,315,930 $ 10,136,736 $ 37,866,345 $ 11,887,160 Addition: Vesting date fair value of awards granted and vesting during such year $ 399,670 $ 109,219 $ 762,602 $ 269,259 $ 823,466 $ 270,477 Addition (Subtraction): Change as of the vesting date (from the end of the prior fiscal year) in fair value of awards granted in any prior fiscal year for which vesting conditions were satisfied during such year $ (11,246,041) $ (2,511,717) $ (2,594,849) $ 156,505 $ (1,085,111) $ 1,805,834 Compensation Actually Paid (as calculated) $ (4,695,030) $ (639,700) $ 65,926,795 $ 23,903,448 $ 79,705,130 $ 27,907,550 * Amounts presented are averages for the entire group of NEOs (excluding our CEO). ** Stock option grant date fair values are calculated based on the Black-Scholes option pricing model as of date of grant. Adjustments have been made using stock option fair values as of each measurement date using the stock price as of the measurement date and updated assumptions (i.e., term, volatility, dividend yield, risk free rates) as of the measurement date. Performance-based restricted stock unit grant date fair values are calculated using the stock price and performance accrual modifiers, where relevant, as of date of grant assuming target performance. Adjustments have been made using the stock price and performance accrual modifier as of the applicable year end and as of the date of vest. Time-vested restricted stock unit grant date fair values are calculated using the stock price as of date of grant. Adjustments have been made using the stock price as of the applicable year end and as of each date of vest. | ||||
| Equity Valuation Assumption Difference, Footnote [Text Block] | Stock option grant date fair values are calculated based on the Black-Scholes option pricing model as of date of grant. Adjustments have been made using stock option fair values as of each measurement date using the stock price as of the measurement date and updated assumptions (i.e., term, volatility, dividend yield, risk free rates) as of the measurement date. Performance-based restricted stock unit grant date fair values are calculated using the stock price and performance accrual modifiers, where relevant, as of date of grant assuming target performance. Adjustments have been made using the stock price and performance accrual modifier as of the applicable year end and as of the date of vest. Time-vested restricted stock unit grant date fair values are calculated using the stock price as of date of grant. Adjustments have been made using the stock price as of the applicable year end and as of each date of vest. | ||||
| Compensation Actually Paid vs. Total Shareholder Return [Text Block] | |||||
| Compensation Actually Paid vs. Net Income [Text Block] | |||||
| Compensation Actually Paid vs. Company Selected Measure [Text Block] | |||||
| Tabular List [Table Text Block] | The most important financial measures used by the Company to link Compensation Actually Paid (as defined by SEC rules) to the Company’s NEOs for the most recently completed fiscal year to the Company’s performance are: Organic Revenue Growth* Adjusted Net Income* Adjusted EPS* Free Cash Flow* Total Shareholder Return | ||||
| Total Shareholder Return Amount | [4] | 170.63 | 206.28 | 143.71 | |
| Peer Group Total Shareholder Return Amount | [5] | 137.66 | 141.38 | 112.97 | |
| Net Income (Loss) | $ 6,960,000,000 | $ 7,728,000,000 | $ 6,377,000,000 | ||
| Company Selected Measure Amount | $ / shares | [1] | 23.24 | 25.13 | 19.56 | |
| PEO Name | Mr. Casper | ||||
| Additional 402(v) Disclosure [Text Block] | These measures are non-GAAP measures. Appendix A to this Proxy Statement defines these and other non-GAAP financial measures and reconciles them to the most directly comparable historical GAAP financial measures. | ||||
| Measure [Axis]: 1 | |||||
| Pay vs Performance Disclosure [Table] | |||||
| Measure Name | Organic Revenue Growth* | ||||
| Measure [Axis]: 2 | |||||
| Pay vs Performance Disclosure [Table] | |||||
| Measure Name | Adjusted Net Income* | ||||
| Measure [Axis]: 3 | |||||
| Pay vs Performance Disclosure [Table] | |||||
| Measure Name | Adjusted EPS* | ||||
| Non-GAAP Measure Description [Text Block] | Adjusted EPS is a non-GAAP measure. Appendix A to this Proxy Statement defines this and other non-GAAP financial measures. | ||||
| Measure [Axis]: 4 | |||||
| Pay vs Performance Disclosure [Table] | |||||
| Measure Name | Free Cash Flow* | ||||
| Measure [Axis]: 5 | |||||
| Pay vs Performance Disclosure [Table] | |||||
| Measure Name | Total Shareholder Return | ||||
| PEO [Member] | Defined Benefit and Pension Plan Amounts Deducted From SCT [Member] | |||||
| Pay vs Performance Disclosure [Table] | |||||
| Adjustment to Compensation Amount | $ 0 | $ 0 | $ 0 | ||
| PEO [Member] | Stock Awards Deducted from SCT [Member] | |||||
| Pay vs Performance Disclosure [Table] | |||||
| Adjustment to Compensation Amount | (20,198,218) | (12,551,562) | (16,282,896) | ||
| PEO [Member] | FV of Equity Awards Granted in Period Outstanding Unvested [Member] | |||||
| Pay vs Performance Disclosure [Table] | |||||
| Adjustment to Compensation Amount | 13,253,670 | 26,760,316 | 31,993,253 | ||
| PEO [Member] | Change in FV of Equity Awards Adj [Member] | |||||
| Pay vs Performance Disclosure [Table] | |||||
| Adjustment to Compensation Amount | (15,113,021) | 32,315,930 | 37,866,345 | ||
| PEO [Member] | Equity Awards Granted and Vested in Period [Member] | |||||
| Pay vs Performance Disclosure [Table] | |||||
| Adjustment to Compensation Amount | 399,670 | 762,602 | 823,466 | ||
| PEO [Member] | Change in FV of Prior Period Awards Vested in Period [Member] | |||||
| Pay vs Performance Disclosure [Table] | |||||
| Adjustment to Compensation Amount | (11,246,041) | (2,594,849) | (1,085,111) | ||
| Non-PEO NEO [Member] | Defined Benefit and Pension Plan Amounts Deducted From SCT [Member] | |||||
| Pay vs Performance Disclosure [Table] | |||||
| Adjustment to Compensation Amount | 0 | 0 | (158,701) | ||
| Non-PEO NEO [Member] | Stock Awards Deducted from SCT [Member] | |||||
| Pay vs Performance Disclosure [Table] | |||||
| Adjustment to Compensation Amount | (3,416,337) | (5,251,850) | (5,319,794) | ||
| Non-PEO NEO [Member] | FV of Equity Awards Granted in Period Outstanding Unvested [Member] | |||||
| Pay vs Performance Disclosure [Table] | |||||
| Adjustment to Compensation Amount | 3,626,807 | 10,357,430 | 10,441,378 | ||
| Non-PEO NEO [Member] | Change in FV of Equity Awards Adj [Member] | |||||
| Pay vs Performance Disclosure [Table] | |||||
| Adjustment to Compensation Amount | (4,391,710) | 10,136,736 | 11,887,160 | ||
| Non-PEO NEO [Member] | Equity Awards Granted and Vested in Period [Member] | |||||
| Pay vs Performance Disclosure [Table] | |||||
| Adjustment to Compensation Amount | 109,219 | 269,259 | 270,477 | ||
| Non-PEO NEO [Member] | Change in FV of Prior Period Awards Vested in Period [Member] | |||||
| Pay vs Performance Disclosure [Table] | |||||
| Adjustment to Compensation Amount | $ (2,511,717) | $ 156,505 | $ 1,805,834 | ||
| [1]Adjusted EPS is a non-GAAP measure. Appendix A to this Proxy Statement defines this and other non-GAAP financial measures.[2]Represents the amount of “Compensation Actually Paid” or “CAP” as computed per SEC rules. These amounts do not reflect the actual amount of compensation earned by or paid to the applicable individual(s) during the applicable year. The following table summarizes the adjustments made to total compensation in accordance with Item 402(v) of Regulation S-K in order to determine the compensation amounts shown in the table above as being “Compensation Actually Paid”.[3]The CEO was Mr. Casper for all years in the table. The other NEOs were Messrs Williamson and Lagarde (all years), Mr. Pettiti (2022 and 2021), Mr. Boxer (2022), Mr. Stevenson (2021 and 2020), and Syed Jafry (2020).[4]For the relevant fiscal year, represents the cumulative total shareholder return of the Company for the measurement periods ending on December 31 of each of 2022, 2021 and 2020, respectively.[5]For the relevant fiscal year, represents the cumulative total shareholder return of a weighted blend (80/20, respectively) of the Standard & Poor’s 500 Healthcare and Standard & Poor’s 500 Industrial Indices (“S&P Index”), our published industry index for purposes of disclosure under Item 201(e) of Regulation S-K, for the measurement periods ending on December 31 of each of 2022, 2021 and 2020, respectively. | |||||